Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1433

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 1433
---
2024 annual period,
and for interim periods beginning in 2025. The impact is limited to our financial statement disclosures, which are presented in Note
2 to the accompanying consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09,
Income Taxes (ASC 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) which requires disaggregated information
about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective
for fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact that ASU 2023-09
will have on our financial statement disclosures.

In November 2024, the FASB issued ASU 2024-03,
Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses (“ASU 2024-03”), which applies to all public business entities that file financial statements
with the SEC. The amendments in this ASU require public business entities to disclose on an annual and interim basis, disaggregated information
about certain income statement expense line items. The new standard is effective for fiscal years beginning after December 15, 2026,
with early adoption permitted. We are currently evaluating the impact that ASU 2024-03 will have on our financial statement disclosures.

Item 7A. Quantitative
and Qualitative Disclosures About Market Risk.

We qualify as a smaller reporting company, as
defined by SEC Rule 229.10(f)(1) and are not required to provide the information required by this Item.

58

Item 8. Financial Statements
and Supplementary Data.

INDEX TO FINANCIAL STATEMENTS

    Report
    of Independent Registered Public Accounting Firm
     
    F-2
  
    Audited
    Consolidated Balance Sheets at December 31, 2024 and 2023
     
    F-3
  
    Audited
    Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023
     
    F-4
  
    Audited
    Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2024 and 2023
     
    F-6
  
    Audited
    Consolidated Statements of Cash Flows for the years